Previous Meeting: 11th Course in 2014

 

Lecture program: Accepted speakers and topics


Special guests

Dr. Mark Murcko

Disruptive Biomedical

Structure-Based Design in Drug Discovery

New Chemical Space

Prof. Dr. Beat Ernst

Univ. of Basel, CH

Glycomimetics

Prof. Dr. Norbert Sewald

Univ. of Bielefeld, D

Peptidomimetics

Prof. Dr. Karl-Heinz Altmann

ETH Zürich, CH

Natural Products

Dr. Nils Jakob Hansen

Vipergen ApS, Copenhagen, DK

DNA-encoded libraries

Dr. Bart DeCorte

Entura, US

Natural Products

Target Families

Dr. Daniel Obrecht

Polyphor, Allschwil, CH

Protein-Protein Interactions

Dr. Paul Brennan

SGC, Oxford, UK

Epigenetics

Dr. Gerhard Müller

Mercachem BV, Nijmegen, NL

Kinases and Inhibitors

Dr. Richard Sedrani

Novartis, Basel, CH

Proteases

Dr. Robert M. Owen

Neusentis/Pfizer, Cambridge, UK

Ion Channels

Dr. Jonathan Mason

Heptares Therapeutics Ltd., Hertfordshire,UK

GPCRs in Structure Based Design

Tactical Aspects in Lead Finding and Optimization

Prof. Dr. David Swinney

iRND3, San Francisco, US

Binding Kinetics

Dr. Richard Morphy

Eli Lilly, UK

Med Chem in CNS space

Dr. Jens-Uwe Peters

Roche, Basel, CH

Polypharmacology

Prof. Dr. Hugo Kubinyi

Heidelberg, D

Metabolism

Dr. Dirk Ullmann

Evotec, München, D

Biophysics

Dr. Nicholas Meanwell

BMS, Princeton, US

Bioisosteres

Dr. Andrew Mortlock

AstraZeneca, UK

Showcases on Lead Finding and Optimization

Dr. Christoph Funk

Roche, Basel, CH

Experimental ADME: Major DMPK Properties to Assess During Lead Optimization

Dr. Juswinder Singh

Avila Therapeutics

Irreversible inhibitors in medicinal chemistry

Case Studies

Dr. Richard Chesworth

Epizyme Inc, Boston, US

Epigenetic Enzyme Inhibitors

Dr. Ray Finlay

AstraZeneca, UK

Tackling Resistance Formation in Kinase Inhibitors

Dr. Sven Ruf

Sanofi, Frankfurt, D

Cathepsin A Inhibitors

Dr. Peter Grootenhuis

Vertex, US

Discovery and Development of Kalydeco for Cystis Fibrosis

 

Tutorials


Topic 

Instructors  Affiliation

Fragment-Based Lead Generation

Michael Mazanetz
Evotec
Evotec

Lead Discovery Showcase

AstraZeneca
Mercachem
Mercachem

NMR in Drug Discovery

MPI Potsdam
Bayer

IP Strategies in Drug Discovery

Frank Schager Actelion

 



Program 2014

 

 

TPL_BEEZ2_ADDITIONAL_INFORMATION